Sign In

Login

Password

Forgot Password ? Sign Up

BOS-580 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "BOS-580" in English language version.

refsWebsite
Global rank English rank
7nih.gov
4th place
4th place
5doi.org
2nd place
2nd place
2semanticscholar.org
11th place
8th place

doi.org (Global: 2nd place; English: 2nd place)

  • Raptis, Dimitrios D.; Mantzoros, Christos S.; Polyzos, Stergios A. (22 January 2023). "Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease". Therapeutics and Clinical Risk Management. 19: 77–96. doi:10.2147/TCRM.S352008. PMC 9879042. PMID 36713291.
  • Yang, Ranyao; Xu, Aimin; Kharitonenkov, Alexei (1 January 2022). "Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver". The Journal of Clinical Endocrinology & Metabolism. 107 (1): e417–e419. doi:10.1210/clinem/dgab686. PMC 8684496. PMID 34529079.
  • Jin, Leigang; Yang, Ranyao; Geng, Leiluo; Xu, Aimin (20 January 2023). "Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications". Annual Review of Pharmacology and Toxicology. 63 (1): 359–382. doi:10.1146/annurev-pharmtox-032322-093904. PMID 36100222. S2CID 252221297.
  • Loomba, Rohit; Kowdley, Kris V.; Rodriguez, Jose; Kim, Nomita J.; Alvarez, Alina Maria; Morrow, Linda; Jeglinski, Brenda; Clawson, Alicia; Chowdhury, Swapan; Bain, Gerard; Odrljin, Tatjana (2025). "Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 10 (8): 734–745. doi:10.1016/S2468-1253(25)00067-6. PMID 40484014.
  • Timmins, Peter (January 2021). "Industry Update: the latest developments in the field of therapeutic delivery, September 2020". Therapeutic Delivery. 12 (1): 7–20. doi:10.4155/tde-2020-0124. PMID 33397151. S2CID 230661884.

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

  • Raptis, Dimitrios D.; Mantzoros, Christos S.; Polyzos, Stergios A. (22 January 2023). "Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease". Therapeutics and Clinical Risk Management. 19: 77–96. doi:10.2147/TCRM.S352008. PMC 9879042. PMID 36713291.
  • Yang, Ranyao; Xu, Aimin; Kharitonenkov, Alexei (1 January 2022). "Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver". The Journal of Clinical Endocrinology & Metabolism. 107 (1): e417–e419. doi:10.1210/clinem/dgab686. PMC 8684496. PMID 34529079.
  • Jin, Leigang; Yang, Ranyao; Geng, Leiluo; Xu, Aimin (20 January 2023). "Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications". Annual Review of Pharmacology and Toxicology. 63 (1): 359–382. doi:10.1146/annurev-pharmtox-032322-093904. PMID 36100222. S2CID 252221297.
  • Loomba, Rohit; Kowdley, Kris V.; Rodriguez, Jose; Kim, Nomita J.; Alvarez, Alina Maria; Morrow, Linda; Jeglinski, Brenda; Clawson, Alicia; Chowdhury, Swapan; Bain, Gerard; Odrljin, Tatjana (2025). "Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 10 (8): 734–745. doi:10.1016/S2468-1253(25)00067-6. PMID 40484014.
  • Timmins, Peter (January 2021). "Industry Update: the latest developments in the field of therapeutic delivery, September 2020". Therapeutic Delivery. 12 (1): 7–20. doi:10.4155/tde-2020-0124. PMID 33397151. S2CID 230661884.

ncbi.nlm.nih.gov

  • Raptis, Dimitrios D.; Mantzoros, Christos S.; Polyzos, Stergios A. (22 January 2023). "Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease". Therapeutics and Clinical Risk Management. 19: 77–96. doi:10.2147/TCRM.S352008. PMC 9879042. PMID 36713291.
  • Yang, Ranyao; Xu, Aimin; Kharitonenkov, Alexei (1 January 2022). "Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver". The Journal of Clinical Endocrinology & Metabolism. 107 (1): e417–e419. doi:10.1210/clinem/dgab686. PMC 8684496. PMID 34529079.

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org